JACOBIO-B(01167): The registration clinical data of the KRAS inhibitor Golerese was published in the medical journal "Nature Medicine".

JACOBIO-B (01167) announced that the registration clinical trial data of the company's independently developed KRAS inhibitor, Goloress, has been published in the medical journal "Nature Medicine". In the article, Jacobio disclosed the complete data of Goloress in treating patients with KRAS G12C mutation second-line or above lung cancer for the first time. Key phase II clinical trial data shows that in second-line non-small cell lung cancer patients treated with Goloress as a single agent, the confirmed objective response rate was 47.9% (56/117), the median progression-free survival was 8.2 months, and the median overall survival was 13.6 months. Goloress has favorable safety characteristics and compared to other KRAS G12C inhibitors, it has good gastrointestinal safety characteristics. Currently, Goloress has been submitted for new drug approval to the National Medical Products Administration Drug Evaluation Center and has been granted priority review.